Fungal Infection News and Research

RSS

CECAD professor receives Prof Pushpa Talwar Memorial Oration for exceptional excellence in medical mycology

Prof Cornely heads the Clinical Trials Center and the Translational Research Platform at the CECAD Excellence Cluster at the University of Cologne. In addition to his research activities, as a senior physician at the Clinic I of Internal Medicine of the Cologne University Hospital he is responsible for clinical therapies for mycological infections.

20 Jan 2014

Rutgers New Jersey Medical School's David Perlin explains how fungal infections can become deadly

Ask someone what the term 'fungus' brings to mind, and chances are it will be an image of something that smells or looks disgusting. Ask David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, and the response will be far more somber - because he knows how deadly fungi can be.

24 Dec 2013

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.

4 Dec 2013

MiniVax wins $20,000 in NOBIC’s second annual BioChallenge business competition

MiniVax, Inc. (MiniVax) participated in the New Orleans BioInnovation Center's (NOBIC) second annual BioChallenge, a business competition part of the three-day Innovation Louisiana 2013 conference.

3 Dec 2013

Dermatologists provide list of specific treatments, procedures not required for medical care

The American Academy of Dermatology today released its list of specific treatments and procedures related to skin health and care that are not always necessary.

29 Oct 2013

Hedgepath, Mayne Repurposing Fungal Infection Drug For Cancer

...

11 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

Burning incense generates indoor air pollutants that may cause inflammation in human lung cells

Burning incense, a popular cultural practice in Arabian Gulf countries and elsewhere, generates indoor air pollutants that may cause inflammation in human lung cells, say researchers in the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.

3 Aug 2013

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals announced today that on July 26, 2013 it submitted its New Drug Application to the U.S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

30 Jul 2013

Researchers develop microbial washing technique to decontaminate fetal tissues

The use of central nervous system fetal tissues derived from routine elective abortions to provide stem cells for transplantation procedures aimed at restoring damage done by neurodegenerative diseases is an established therapy.

23 Jul 2013

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Moberg Pharma AB today announced that Menarini Asia-Pacific, a member of the Menarini Group - a top 40 global pharmaceutical company - has been granted the exclusive rights to market and sell Kerasal Nail in China. The companies now intend to seek marketing authorization for the product in the Chinese market.

22 Jul 2013

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract "Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail Onychomycosis" was accepted for oral presentation at the 2013 APMA Annual Scientific Meeting (The National) to be held in Las Vegas, Nevada.

19 Jul 2013

University of Manchester, F2G to develop new antifungal drug for fungal infections

F2G Ltd and The University of Manchester Announce a new €6.1million project to develop new antifungal agents to treat resistant fungal infections.

26 Jun 2013

Report alerts clinicians, public about catastrophic dangers of contaminated epidural injections

Investigators from the Centers for Disease Control and Prevention describe pathologic findings from 40 case reports of fungal infection in patients who had been given contaminated epidural, paraspinal, or intra-articular (into joints) steroid injections and correlate these findings with clinical and laboratory data.

26 Jun 2013

UT candidate wins AHA fellowship to support research in cardiovascular, stroke discoveries

University of Texas at San Antonio biomedical engineering Ph.D. candidate Anand Srinivasan has been awarded a $25,000, one-year doctoral fellowship from the American Heart Association (AHA).

20 Jun 2013

Spinal infection at contaminated drug injection site detected using contrast-enhanced MRI screening

Magnetic resonance imaging (MRI) at the site of injection of a contaminated lot of a steroid drug to treat symptoms such as back pain resulted in earlier identification of patients with probable or confirmed fungal spinal or paraspinal infection, allowing early initiation of medical and surgical treatment, according to a study in the June 19 issue of JAMA.

19 Jun 2013

Innovative approach helps Virginia mount effective response to contaminated steroid crisis

An innovative "hybrid" surveillance strategy-highlighted by close cooperation between public health officials and clinical partners-helped Virginia mount an efficient and effective response to the ongoing outbreak of fungal meningitis and other infections, according to a report in the July/August issue of Journal of Public Health Management and Practice.

31 May 2013

Common sugar molecule promising target for development of broad-spectrum vaccine

Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges-one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens.

28 May 2013

Nobel Prize recipient describes on innate immunity at Annual Drosophila Research Conference

A young scientist's astute observation - that grasshoppers don't get sick - eventually led to profound insights into our own immunity.

6 Apr 2013

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

28 Feb 2013